



ADAP Advocacy
PO Box 846
Nags Head, NC 27959

adapadvocacy.org

Board of Directors:

Chair
Jen Laws
Slidell, LA

Secretary
Guy Anthony
Brooklyn, NY

Treasurer
Wanda Brendle-Moss, R.N.
Winston-Salem, NC

Erin Darling, Esq.
Washington, DC

Robert "Bobby" Dorsey, Esq.
Washington, DC

Eric Flowers
Oakland, CA

Lyne Fortin, B.Pharm, MBA
Montreal, Canada

Hilary M. Hansen
Washington, DC

Lisa Johnson-Lett
Birmingham, AL

Theresa Nowlin
Dorchester, MA

Shabbir Imber Safdar
San Francisco, CA

Jennifer Vaughan
Watsonville, CA

Marcus A. Wilson
Orlando, FL

CEO
Brandon M. Macsata
Washington, D.C.

Directors Emeritus:
Michelle Anderson
William Arnold – *in memoriam*
John D. Kemp, Esq.
Gary Rose – *in memoriam*
Joyce Turner Keller
Rani Whitfield, M.D.

ADAP Advocacy Unveils Survey on Long-Acting Injectables for HIV Prevention

Survey Seeks Patient Perspectives from People Who are HIV-Negative on Long-Acting Injectables HIV Pre-Exposure Prevention

For Immediate Release:

February 1, 2024

Media Contact:

info@adapadvocacy.org

WASHINGTON, D.C. – ADAP Advocacy today, as part of its Long-Acting Injectables (LAIs) Project, launched an [online survey](#) to gain better patient perspectives from people who are HIV-negative about approved LAI medications for HIV Pre-Exposure Prophylaxis (PrEP). The online survey is open to people who are **HIV-Negative** and **residing in the United States** and its Territories.

LAIs are prescription medications designed to either prevent the transmission of HIV or treat HIV over an extended period. These medications can be used to replace daily oral medications. However, anecdotal evidence suggests that access barriers remain.

“Obstacles and operational barriers to timely access of new agents, including HIV pre-exposure injectables, have increased with the advent of newer injectable therapies,” **summarized Riley Johnson, Project Manager of the ADAP Advocacy’s Long-Acting Injectables Project.** “The barriers that commonly occur hinder equitable access for HIV-negative people who are seeking Injectable PrEP, regardless of their health insurance status. Our survey provides patients not living with HIV an opportunity to share their experiences trying to access this prevention tool.”

The U.S. Food & Drug Administration (FDA) recently approved the first long-acting injectable for use in at-risk adults and adolescents for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV. ViiV Healthcare’s [Apretude](#) (cabotegravir extended-release injectable suspension) is the first LAI on the market for HIV prevention.

HIV-negative persons can take the survey, here <https://cutt.ly/PrEP-Survey>.

ADAP Advocacy’s Long-Acting Injectables Project is made possible with support from Gilead Sciences, Merck, and ViiV Healthcare.

To learn more about ADAP Advocacy, AIDS Drug Assistance Programs, or its Long-Acting Injectables Project, please email info@adapadvocacy.org.

####

About ADAP Advocacy: ADAP Advocacy’s mission is to promote and enhance the AIDS Drug Assistance Programs (ADAPs) and improves access to care for persons living with HIV/AIDS. ADAP Advocacy works with advocates, community, health care, government, patients, pharmaceutical companies, and other stakeholders to raise awareness, offer patient educational programs, and foster greater community collaboration.